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 TAXONOMY AND TRANSPARENCY IN 
INTERNATIONAL PHARMACEUTICAL 
NOMENCLATURE 
Rachel Bryan 
The language of medicine, although highly specialised, has a broad 
usership comprising multiple strata of the population with varying levels 
of knowledge for multiple purposes. This usership includes general 
practitioners, consultants, nurses, pharmacists, patients, parents and 
caregivers. No single person holds a comprehensive knowledge of every 
area, and so there is great variation in understanding of the terminology 
and the degree to which its use is specialised. Medication names such as 
morphine, Benadryl, paracetamol and adrenaline surround us in our daily 
lives, and are an important and under-researched area of terminology. 
In antiquity, medications were named after the gods, e.g. morphine 
after Morpheus, the god of dreams and anandamide after Sanskrit ananda, 
‘bliss, delight’ (OED). In the present day, pharmaceutical substances are 
named within a complex system of nomenclature which is managed by 
multiple government bodies. As illustrated in Figure 1, a pharmaceutical 
substance such as salbutamol (an asthma medication) will have three types 
of name. 
 
Figure 1. The pharmacopoeial monograph1 for salbutamol 
                                                          
1 A pharmacopoeial monograph is a single document describing the name(s) and 
chemical formula of a pharmaceutical substance. 
 One chemical name, based upon the chemical formula of the 
substances, indicating the position of hydroxy groups, the length of 
the carbon chain, and so on. This name is designated by the 
International Union of Chemistry, and is published multilingually. 
There are some interesting translation problems in this area, but they 
are beyond the scope of this chapter. 
 At least one brand, or proprietary, name, chosen by the manufacturer 
that originally created the substance. This name is commercially 
driven, capitalised and legally bound to not imply any therapeutic 
benefit. It is typically laconic and euphonious. Once out of patent (up 
to 20 years in the EU), a substance can be marketed by other 
companies and so will be assigned more brand names. 
 At least one generic, or nonproprietary name. On a global level, it will 
be assigned an International Nonproprietary Name (INN) by the 
World Health Organization (WHO), and in each country in which it is 
approved for use, it will be assigned a national generic name, such as 
a British Approved Name (BAN) in the UK, or a Denominazione 
Comune Italiana (DCIT) in Italy. 
1 International Nonproprietary Names 
This chapter presents a qualitative analysis of the International 
Nonproprietary Name (INN) nomenclature, focusing in particular on the 
underlying conceptual taxonomy and semantic transparency. INNs will be 
the focus of this study as they are the most commonly used system of 
generic names, and their form is used by default in both the UK and the 
EU with only a few notable exceptions (Aronson 2000). There are over 
8,000 INNs currently in use. INNs are designated by the WHO, and 
formally placed in the public domain to promote consistency of global 
communications between manufacturers, clinicians, prescribers and 
patients. The nomenclature is published in six languages (WHO 1997). 
Given their international status, the name designation process in place 
must encompass a broad conceptual system and naming guidelines must 
be robust and stringently applied. 
INNs are designated according to a set of guidelines (WHO 1997), 
which aim to achieve usability (pronounceable, legible, audibly 
perceptible, comprehensible and memorable), clarity (free from confusion) 
and taxonomy (showing relationship within the conceptual system). The 
WHO dictates that pharmacological relationship be shown by using a 
common ‘stem’, which may be a prefix, infix, suffix, or a ‘freefix’, which 
can appear anywhere in the name. A ‘stem’ in this context is a word part 
to which a particular pharmacological meaning has been assigned, and 
which is used to signify the relationship between substances. By using a 
common stem, substances are placed into pharmacological groups, related 
by anatomical target, therapeutic action, or chemical composition. The use 
of stems creates a taxonomic conceptual system for INN, and allows users 
to exploit this systematicity to increase retention, pronunciation and 
recognition of the names. 
The INNs programme began in 1952, and between 120 and 150 new 
names are designated each year. They are first created in Latin, and this 
form is translated into the six official languages of the United Nations: 
English, French, Spanish, Russian, Chinese and Arabic. The Latin form of 
the name is used for translation of the nomenclature into other European 
languages, such as Italian and Portuguese (Mareckova et al. 2002). 
Morphosemantic analysis of INNs is possible because their meaning is 
highly compositional, i.e. meaning is derived from the meanings of 
constituent parts (Deléger et al. 2009). In contrast to medical terminology 
in anatomy and general medicine, INNs are not full neoclassical 
compounds in that they cannot be parsed into elements directly derived 
from classical languages. INNs are composed of a random element, 
normally a prefix, and at least one stem. Stems are formed from three 
types of component. These types are listed in (1). 
(1) a. abbreviations, such as the sub-stem -tu- in situximab 
denoting targeting tumorous tissue, or the stem -kin in 
ilodecakin denoting interleukin type substances; 
b. acronyms, such as the stem -mab in urtoxazumab denoting 
monoclonal antibodies; and  
c.  elements of chemical nomenclature. These can be seen as 
adapted neoclassical forms, such as the stem -fos (from 
Latin phosphorous) in clofenvinfos, denoting phosphorous 
derivatives. 
2 Why is this important?  
The World Health Organisation (WHO) cites globalisation, consumerism, 
growth in free markets, increased cross-border communication and the 
ubiquity of the Internet as agents of change in medicine and 
pharmaceuticals, giving rise to new safety concerns. Furthermore, the 
increasingly global trade in pharmaceuticals and higher levels of 
regulatory complexity have impelled many intergovernmental 
organisations to make efforts towards harmonisation of regulatory 
activities to ensure consistent efficacy of pharmacovigilance efforts (WHO 
2002). 
Medication errors make up a high proportion of all patient safety 
events (Jordan & Kyriacos 2014; Ostini et al. 2012), and some result in 
overdose or adverse drug reactions, and can cause serious harm to patients 
(Aronson 2009; Runciman et al. 2003). Medication incidents in the UK 
resulted in 50 deaths between October 2011 and September 2012 (Jordan 
& Kyriacos 2014). It is estimated that medication errors cost the USA 
between $15 and 28bn each year, and that the USA spent an additional 
$213bn (8% of total healthcare spend) in 2012 on costs arising from 
medicines’ mismanagement, including medication errors (Aitken & 
Valkova 2013). 
Medication errors may be a result of medicines having names that look 
alike or sound alike, and are referred to as LASA errors. Examples of 
confused LASA pairs are given in (2). 
(2) a. mercaptopurine-mercaptamine. A 9-month-old infant 
presented with nephropathic cystinosis, and was prescribed 
mercaptopurine by the GP instead of mercaptamine. After a 
month on the wrong medication, she developed 
pancytopenia but ultimately made a full recovery (MHPRA 
2010).  
b. hydromorphone-morphine. An elderly patient was 
discharged after being administered hydromorphone instead 
of the prescribed morphine, by a nurse in the Emergency 
Department. He suffered a fatal respiratory arrest on his 
way home. 
LASA errors are estimated to account for around 25% of all medication 
errors in the US (Emmerton & Rizk 2012), and occur in all aspects of 
medications management – during prescribing, dispensing and 
administration of the medication. LASA errors thus represent a significant 
threat to patient safety. 
The bulk of extant literature on LASA errors focuses on mitigating 
their occurrence (Emmerton and Rizk 2012; Ghaleb et al 2010, Aronson 
2009; Kovacic and Chambers 2011), and very little research has been 
conducted into linguistic properties of the nomenclature to elucidate 
properties that may prime the risk of the errors occurring. Profiling of such 
properties could inform the name formation process and thus 
prophylactically reduce the risk to patient safety. It is also possible that 
elucidating external factors contributing to the likelihood of confusion 
error (such as high syllabic similarity) will encourage reporting of adverse 
drug events (ADEs) and near misses, since these may be under-reported 
due in part to fear of reprisal, blame and reputation damage (Aronson 
2009). 
More needs to be known about the formal and semantic properties of 
the main global medication nomenclature of International Nonproprietary 
Names. This study examines semantic transparency in the nomenclature, 
and the underlying conceptual taxonomy of pharmacological relationship. 
In the context of this study, semantic transparency is defined as the 
correspondence between form and meaning within a lexical unit, and the 
extent to which meaning motivates form and meaning is derived from 
form. 
3 Medical taxonomies and ontologies 
There are many systems of classification in medicine, such as the HUGO 
(HUman Genome Organisation) gene nomenclature, Medical Subject 
Headings (MeSH) used to index published research on Medline, and the 
University of Washington Digital Anatomist (UWDA) (Shapiro et al. 
2005; Segura-Bedmar et al. 2008). Due to the exponential growth of 
published research in medicine, it is now impossible for specialists to keep 
abreast of developments in their field, and the need has arisen to automate 
recognition of key concepts in the literature (Coletti & Bleich 2001, 
Segura-Bedmar et al. 2008). The Unified Medical Language System 
(UMLS) is an example of an ontology by which automated software can 
read and assimilate information in published research (Segura-Bedmar et 
al. 2008), and encompasses various nodes such as the UWDA for anatomy. 
Some systems determine nomenclature, such as the HUGO gene 
nomenclature, and others are used to assign conceptual relations, such as 
the UWDA (Shapiro et al. 2005). The UWDA uses various semantic links, 
e.g. the oesophagus is part-of the foregut, continuous-with the pharynx and 
stomach, and adjacent-to the trachea and thoracic aorta and thoracic 
vertebral column. 
The terms classification, taxonomy and ontology are often used 
interchangeably to refer to any system of categorisation, but for the 
purposes of this study, ontology is taken to mean any system that 
categorises concepts (Stevens et al. 2000) and a taxonomy should be seen 
as a methodology for categorisation. There are several key distinctions to 
be made. An ontology is “the concrete form of a conceptualisation of a 
community’s knowledge of a domain” (2000: 1), whereas a taxonomy 
does not necessarily include added knowledge beyond the necessary and 
sufficient criteria for categorisation. Ontologies may be multidirectional 
and include multiple types of semantic relation, such as meronymy and 
metonymy, whereas a taxonomy is an upside down tree structure (Shapiro 
et al. 2005) and is based upon intrinsic properties of its members. 
Taxonomies are typically ‘tree-like’ hierarchies, employing hyponymy (is-
a, class membership) to express semantic relationship. Under classical 
Jackendovian theory, the organisation of systems will inevitably depend 
upon our conceptualisation of the world (Jackendoff 1983), but further 
consideration of that is beyond the scope of this chapter. The prototypical 
taxonomy is the plant or animal kingdom used in biology (Shapiro et al. 
2005, Coletti & Bleich 2001). 
According to the WHO, the INN system is a ‘classification’, but can be 
more specifically defined as a taxonomy since it only employs is-a, 
hyponymic semantic relations. Although there is a global taxonomic 
system for pharmaceutical substances, the Anatomical Therapeutic 
Chemical (ATC) index, INNs use a different taxonomy that does not align 
with the ATC (Segura-Bedmar et al. 2008) and is not used by any other 
organisation. For example, the medication name selegiline in the ATC 
system would be found by drilling down into the taxonomy: Nervous 
system > Anti-parkinson drugs > Dopaminergic agents > Monoamine 
oxidase B inhibitors, but in the INN system by Psychopharmacologics > 
Antidepressants > Monoamine oxidase inhibitors. 
The INN system employs at most a four-level taxonomy, and assigns 
alphanumeric codes to each level. Although there is room for four levels, 
currently names fill only two levels, so the INN system can be seen as a 
flat taxonomy, or a collection of individual taxa under an undefined 
hyperonym. There is sparse information on the taxonomy beyond the 
statutory guidance of the WHO, and neither definitions nor necessary and 
sufficient criteria for inclusion in the taxonomy are provided. The INN 
system is unique in the world of medical ontologies and taxonomies in that 
the nomenclature it motivates is used by people at all levels of society with 
all levels of knowledge. 
4 A typology of taxa in the INN nomenclature 
Pharmacological relationships between substances are demonstrated by the 
use of a common stem (WHO 1997: 1), which may be a prefix, infix, 
suffix, or a ‘freefix’. By using a common stem, the INN indicates that its 
denoted substance belongs to a group of substances with similar 
pharmacological activity (WHO 1997: 1). The common stem or sub-stem 
is combined with a “random, fantasy prefix”, normally chosen by the 
submitter of the new substance (WHO 1997: 6), and “the only requirement 
is to contribute to a euphonious and distinctive name” (WHO 2004: 128). 
Displaying taxonomy from right to left, starting at the end of the name, is 
a predictable approach for the user as they can first categorise the name 
under its stem, and further sub-categorise under sub-stems by reading to 
the left. The reverse would be impossible due to the meaningless prefix. 
The INN taxonomy is based upon hyponymy, and in this chapter, stem 
will be used to denote hyperonym, and sub-stem to denote hyponym. 
This chapter presents a qualitative typology of taxa found in the INN 
nomenclature, and reviews the implications of these types in the usability 
of INNs. WHO guidance stipulates that names must not be liable to 
confusion and that relationship must be shown by the use of a common 
stem. Therefore, there must be a robust and structured underlying 
conceptual taxonomy in place to facilitate correct usage of the medication 
names. The typology that follows is a qualitative analysis of the author’s 
database of monolexic INNs (n=7,111) and the WHO Stem Book 2011, 
which provides information on the INN taxonomy and lists of INNs 
containing each stem and sub-stem (WHO 2011). 
4.1 Single-level taxa 
There are many INNs that are regularly formed, some with only a single-
level taxon represented by a single stem. This taxon has no hyponyms. 
Examples are given in Table 1. These stems occur as all four types of 
affix: infix, freefix, prefix and suffix. 
 
Stem 
Affix 
type 
Pharmacology 
Examples of 
INNs 
arte- prefix 
antimalarial agents, 
artemisinin related 
compounds 
arteflene, 
arterolane 
-coxib suffix 
selective cyclo-
oxygenase inhibitors 
etoricoxib, 
tilmacoxib 
-formin suffix 
antihyperglycaemics, 
phenformin derivatives 
benfosformin
, metformin 
nab freefix 
cannabinoid receptors 
agonists 
menabitan, 
nonabine 
-pris- infix 
steroidal compounds 
acting on progesterone 
receptors 
ulipristal, 
asoprisnil 
Table 1: Examples of single-level taxa 
These single-level taxa illustrate the longevity of the INN nomenclature: 
from its inception in 1952, the taxonomy has allowed for developments in 
pharmacology by creating empty pharmacological taxa. Stems are created, 
but may not appear in names immediately – the system is proactive rather 
than reactive. This future-proofing is similar to Dmitri Mendeleev’s 
periodic table, in which gaps were left for elements not yet discovered. It 
is possible that in future a sub-category of cannabinoid receptors agonists 
may be discovered, and in that case a sub-stem of nab can be created. 
4.2 Regular taxa 
Many stem taxa clearly display their taxonomy in names that can be 
interpreted from right to left. The stem is the suffix, and sub-stems are 
distinguished from their co-hyponyms as infixes directly before the suffix 
stem. The taxon for “antiasthmatic, antiallergic substances not acting 
primarily as antihistaminics” has the stem -ast, and sub-
stems -lukast, -milast, -trodast and -zolast. Montelukast is a substance in 
this group, and its meaning can be easily derived from the order of word 
parts: the suffix stem -ast can be used to categorise the substance as part of 
the antiasthmatic taxon, and the infix -luk- can be used to further sub-
categorise it as a leukotriene receptor antagonist. 
In regular taxa such as these, morphemic concatenation is ordered as in 
Table 2. 
 
Random 
prefix 
Sub-stem 
(distinguishing 
part) 
Stem 
INN 
andol  ast andolast 
monte luk ast montelukast 
teto mil ast tetomilast 
sero trod ast serotrodast 
qua zol ast quazolast 
Table 2: Morphemic concatenation in the -ast stem taxon 
4.3 Monoclonal antibodies: a complex and regular taxon 
Monoclonal antibodies are a relatively new but rapidly growing branch of 
biochemistry, and their INN taxon is complex but well defined. There is a 
regular correspondence between names in this group and their meaning, 
and meaning is predictable for the user. INNs for monoclonal antibodies 
comprise a random prefix, followed by two infixes and a stem referring in 
a specified order to: 
 the target class or disease class; 
 the source class on which the immunoglobulin sequence is based; and  
 the hyperonym -mab.  
Each of the three meaning-bearing elements must be defined in the name 
and concatenated in a certain order, but they combine freely with each 
other. 
In this complex and regular taxon, morphemic concatenation is ordered 
as in Table 3. 
 
Ran-
dom 
prefix 
Sub-stem 1 
(target of 
medication) 
Sub-stem 2 
(source of 
antibody) 
Stem INN Description 
icru c u mab icrucumab 
targeting 
cardiovascular 
system, of 
human origin 
siru k u mab sirukumab 
targeting 
interleukin, of 
human origin 
ce tu xi mab cetuximab 
targeting 
tumours, of 
chimeric origin 
ur toxa zu mab 
urtoxa-
zumab 
targeting toxin, 
of humanized 
origin 
Table 3 Morphemic concatenation in the -mab stem taxon 
The complete -mab taxon is shown in Table 4. 
 
sub-stem 1 - 
target 
sub-stem 2 - 
source 
stem   
  -mab monoclonal antibody 
 -a-  rat 
 -axo-  rat/mouse 
 -e-  hamster 
 -i-  primate 
 -o-  mouse 
 -u-  human 
 -xi-  chimeric 
 -xizu-  chimeric/humanised 
 -zu-  humanised 
-b(a)-   bacterial 
-c(i)-   cardiovascular 
-f(u)-   fungal 
-k(i)-   interleukin 
-l(i)-   immunomodulating 
-n(e)-   neural 
-s(o)-   bone 
-tox(a)-   toxin 
Table 4 -mab stem taxon 
There are eight infixes to denote the target class and nine infixes to denote 
the source class, although not all of these are currently used in INNs. 
These may be combined freely with each other but the order in which they 
appear in the word is fixed. As an example, urtoxazumab, which refers to 
a humanised monoclonal antibody directed against a type of toxin-
producing Escherichia Coli (E. Coli), can be decomposed as ur-toxa-zu-
mab, in which -toxa- indicates that it targets a toxin, and -zu- indicates that 
it is humanized (derived from a non-human antibody, which has been 
engineered to be more homologous with human antibodies). This is not an 
example of a three-tiered taxonomy, but rather two mutually independent 
parameters of classification under a single hyperonym. 
Infixes have two forms depending on the following letter; for example, 
-tox(a)- is realised as -toxa- in the above example because it is followed by 
a consonant. In actoxumab, it is realised as -tox- because it is followed by 
the vocalic infix -u-. Without optional linking elements, INNs may contain 
phonemes outside the phonotactics of English (such as *urtoxzumab) and 
thus run the risk of being mispronounced and misunderstood. In names for 
monoclonal antibodies, meaning is conveyed in almost every component 
of the word, and even in a single letter, thus optimizing the space available 
and minimizing character redundancy. 
4.4 Irregular display of taxonomy 
For names within some taxa, there are very clear concatenation rules for 
stems and sub-stems. For example, in names for monoclonal antibodies 
the distinguishing part of the hyponym is prefixed to the stem of its 
hyperonym in the word. However, often the formation of sub-stems for 
hyponyms of a main stem is not consistent in INNs, given the variation in 
types of affix used. The taxon for antivirals, with the stem vir, will be used 
as an example. As a freefix, the stem vir can appear anywhere in the name, 
meaning that the user cannot rely on a right-to-left display of taxonomy to 
derive the meaning. The stem has sub-stems -
amivir, -cavir, -ciclovir,  -fovir, -gosivir, -navir, -previr, -virine and -viroc.  
In irregular taxa such as these, there are two orders of morphemic 
concatenation, exemplified in (3). 
(3) a. alamifovir (random prefix: alami; distinguishing part of 
sub-stem: -fo-; stem: vir) 
b. vicriviroc (random prefix: vicri; stem: vir; distinguishing 
part of sub-stem: -oc) 
The meaning of alamifovir in (3a) can easily be derived from the order of 
morphemic concatenation in the name. However, in vicriviroc in (3b), the 
distinguishing part of the hyponymic sub-stem -viroc follows its 
hyperonym in the name, and thus it is not immediately obvious to which 
taxon the name belongs. A user may mistakenly categorize the name under 
the stem *-oc, which does not exist. This can also be seen in other stem 
taxa, such as the hyperonym prost with hyponym -prostil, and in any 
taxon for which the stem is not a suffix. This problem arises from the 
phenomenon of freefixes in INNs. As stems such as vir and prost do not 
have a set position in the word, semantic transparency may be low since 
the user has no predictable way of recognizing the main stem. 
4.5 Morphosemantics 
As is clear from regular stem taxa and the monoclonal antibodies taxon, 
morphemic order is important for the easy recognition of INNs. When 
stems are suffixes and sub-stems are infixes, taxonomy is displayed and 
semantic transparency is high. 
In some stem taxa, meaning is motivated solely by morphemic order: 
sub-stems take the same form as the stem and are distinguishable only by 
their affix type. The -fos stem taxon denoting “insecticides, anthelminthics, 
pesticides etc, phosphorous derivatives” will be used as an example. 
When -fos is used as a suffix, it is the hyperonym of the taxon. When it 
appears as an infix or a prefix, it is the hyponym denoting “various 
pharmacological categories belonging to fos, other than those above” (an 
insufficient differentiation, but nonetheless confirming its hyponym status). 
This messy taxon may be mistaken for a single category with a freefix 
stem, but in fact the position of the stem in the name motivates meaning. 
Freefixes disturb semantic transparency in INNs by creating 
unpredictability in morphemic order, and they cause inconsistency. Users 
must learn that in some cases meaning depends on the position of the stem 
in the name, and that in other cases position does not matter. 
4.6 Allomorphy 
A stem may have several orthographic allomorphs, illustrated by the 
examples in Table 5. These are variant forms of the stem that do not 
indicate a change in meaning. Allomorphy in this sense can be dangerous: 
when pharmacological relationship is differentiated in units as small as a 
single letter, allomorphs such as -profen and -profene may lead to 
confusion in other areas. For example, -fenin and -fenine are separate stem 
families denoting “diagnostic aids; (phenylcarbamoyl)methyl 
iminodiacetic acid derivatives” and “analgesics, glafenine derivatives”, 
respectively, but are only distinguished by a final letter -e. Variation in the 
orthographic form of stems under a common hyperonym can obfuscate 
meaning, and may also falsely suggest a relationship where there is none. 
 
Official stem Examples 
Allo-
morphs 
Examples 
-azepam (diazepam 
derivatives) 
diazepam, 
lorazepam 
-azam;  
arfendazam, 
clobazam 
-cillin (antibiotics, 6-
aminopenicillanic acid 
derivatives) 
penicillin, 
amoxicillin 
-cillide;  
-cillinam 
libecillide; 
bacmecillinam, 
pivmecillinam 
-eridine (analgesics, 
pethidine derivatives) 
morpheridine, 
properidine 
-ethidine 
pethidine2, 
hydroxy-
pethidine 
-izine (diphenylmethyl 
piperazine derivatives) 
cetirizine, 
cyclizine 
-yzine hydroxyzine 
-mantadine (adamantane 
derivatives) 
amantadine, 
somantadine 
-mantine;  
-mantone 
memantine, 
dopamantine; 
idramantone 
-profen (anti- ibuprofen, -profene aprofene, 
                                                          
2 The example of pethidine highlights the difference between the accepted 
linguistic use of ‘stem’ and the use of ‘stem’ in the context of INNs. In 
pethidine, -ethidine is the stem, and p- is the ‘random prefix’ assigned to 
distinguish it from others in its ‘stem family’. 
 
inflammatory agents, 
ibuprofen derivatives) 
tetriprofen diprofene 
-tril (endopeptidase 
inhibitors) 
dexecadotril, 
candoxatril 
-trilat 
omepatrilat, 
sampatrilat 
-triptyline 
(antidepressants, 
dibenzo[a,d]cycloheptane 
or cyclopheptene 
derivatives) 
nortriptyline, 
butriptyline 
-tiline 
levoprotiline, 
oxaprotiline 
Table 5: Allomorphy 
5 Discussion 
As with Saussure’s two sides of a piece of paper (Sanders 2004), the 
formal and semantic aspects of language are inextricably linked: formal 
aspects of INNs are motivated by their underlying semantics, and although 
the formal realisation of INNs may be conducive to conveying meaning, it 
can equally misrepresent meaning and increase the risk of confusion. 
Although meaning is primarily derived through the taxonomic system of 
stems and sub-stems, it is also motivated by the class of affix and the 
ordering within the name of stems and sub-stems. 
The pharmaceutical nomenclature and its peripheral systems of 
nomenclature are large and complex. A taxonomic conceptual system 
developed over a number of decades will inevitably contain some broken 
links and general inconsistencies, but these inconsistencies should not 
work to the detriment of the overall aim of the system. The structure of the 
INN taxonomy does not conform to the archetypal tree structure, and is at 
times messy and fractured. Properly structured taxonomies help to bring 
substantial order to a model, whereas improperly structured taxonomies 
make models confusing and difficult to use (Guarino and Welty 2000). A 
robust taxonomy is also important for automated recognition systems, and 
this will increase the life-span and usage of the INN nomenclature 
(Segura-Bedmar et al. 2008). 
Semantic motivation in International Nonproprietary Names is 
multifaceted, encompassing multiple methods of conveying meaning. The 
INN nomenclature does not sufficiently exploit formal aspects of language 
by using a systematic and linear ordering of stems and sub-stems in the 
word, thus resulting in pharmacologically related sub-stems that appear to 
be unrelated, such as -ciclovir and -viroc. This type of hyponymy defeats 
the object of a nomenclature to reflect a deep classification of concepts, as 
the formal realization gives no indication of its paradigmatic relations. Of 
course, there are many instances of nested concepts that are mirrored in 
the formal realisation, such as the naming of monoclonal antibodies with 
the stem -mab and two systems of infix sub-stems, and the designation of 
single stems that do belong to a taxon of related stems does not present too 
many problems. 
This means that there is no single way for a user to predict meaning, 
and the burden of learning on clinical users (pharmacists, nurses, 
physicians, medical students) is high. They must understand not only the 
meanings of stems and the layout of the taxonomy, but also the 
inconsistencies peculiar to each stem taxon. They need to know that 
meaning may be motivated at the morphemic level by the class of affix 
and the morphemic concatenation of stems and sub-stems, and to know 
when to ignore spelling variation and when to take note of a single letter 
bearing meaning. It is little wonder that in practice, clinicians rely instead 
on the gradual learning of whole names and memorize them based upon 
their spelling and phonology (personal communication with Dr. Sue 
Jordan, Swansea University). Many stem taxa, such as those for 
monoclonal antibodies, are complex but regular, and there is a predictable 
display of taxonomy and correspondence between form and meaning. 
Semantic transparency in many of the resulting names is low, and marred 
by inconsistency. 
The exact interplay between transparency and similarity is currently 
unclear, since preliminary observations I made suggest that in some cases, 
transparency will increase orthographic similarity between names and thus 
increase the risk of confusion, yet without transparency, users would need 
to learn thousands of names by rote. Given the risk to patient safety in this 
rapidly expanding field, the system of international pharmaceutical 
nomenclature certainly warrants further linguistic investigation. 
6 Conclusion 
INNs carry out different functions depending on the user, and thus they 
must be understandable at multiple levels. For patients and non-
professionals they must be recognisable and pronounceable, but at the 
same time, they must ‘whisper’ in the ear of health professionals by 
communicating meaning through neoclassical compounds and the general 
norms of pharmaceutical nomenclature. To facilitate the correct realisation 
of each INN in all four modalities of language (listening, reading, 
speaking and writing) and thus to prevent confusion between INNs, it is 
imperative that formal aspects are controlled and fully optimised. 
The WHO has been described as the “locus of efforts to improve 
global health … which is the foundation for peace and prosperity” 
(Council for Foreign Relations 2012). Global stewardship is an essential 
role of the WHO, in how it identifies needs to be met and takes a 
leadership role in setting global norms (Clark et al. 2010). Given the 
primary objective of the WHO, “the attainment by all peoples of the 
highest possible level of health”, the INN programme must always be 
viewed from the perspective of patient safety. By creating an international 
nomenclature that is publicly available worldwide, it acts as a fulcrum 
between various institutions operating within separate strata of the 
pharmaceutical industry and inevitably paves the way for more global 
consistency and communication, ultimately enhancing the safety of 
patients. 
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